Stock Events

Stock Events

Intellia Therapeutics 

$12.74
604
+$0.06+0.47% Friday 19:59
+$0.10+0.78%Friday 23:52After hours

Statistics

Day High
12.96
Day Low
12.52
52W High
28.25
52W Low
7.95
Volume
2,789,894
Avg. Volume
4,675,720
Mkt Cap
1.79B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.33
-1.15
-0.98
-0.8
Expected EPS
-0.800716
Actual EPS
N/A

Financials

-609.85%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
67.67MRevenue
-412.69MNet Income

Analyst Ratings

21.64Average Price Target
The highest estimate is 49.00.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
36%
Hold
45%
Sell
18%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NTLA. It's not an investment recommendation.
NVIDIA
125
NVDA
CRISPR Therapeutics
112
CRSP
Microsoft
106
MSFT
Tesla
106
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine operates in the CRISPR gene editing space, directly competing with Intellia's gene editing therapies.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is a leader in the development of CRISPR/Cas9 technology, making it a direct competitor in gene editing.
Beam Therapeutics
BEAM
Mkt Cap3.03B
Beam Therapeutics uses base editing, a form of gene editing that competes with Intellia's CRISPR/Cas9 technology.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, an alternative to CRISPR-based gene editing, posing competition in genetic disease treatment.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals develops RNA-targeted therapies, which can be seen as an alternative to CRISPR-based approaches like Intellia's.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical focuses on enzyme replacement therapies, which can compete with gene editing for certain genetic disorders.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals collaborates on CRISPR therapies and develops treatments for genetic diseases, competing in similar areas as Intellia.

About

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Show more...
CEO
John Leonard
Employees
377
Country
United States
ISIN
US45826J1051
WKN
000A2AG6H

Listings

XETRA
DE
38I.XETRA
STU
DE
38I.STU
MU
DE
38I.MU
F
DE
38I.F

0 Comments

Share your thoughts

FAQ

What is Intellia Therapeutics stock price today?▼
The current price of NTLA is $12.74 USD — it has increased by +0.47% in the past 24 hours. Watch Intellia Therapeutics stock price performance more closely on the chart.
What is Intellia Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Intellia Therapeutics stocks are traded under the ticker NTLA.
Is Intellia Therapeutics stock price growing?▼
NTLA stock has fallen by -1.01% compared to the previous week, the month change is a +16.13% rise, over the last year Intellia Therapeutics has showed a +5.64% increase.
What is Intellia Therapeutics market cap?▼
Today Intellia Therapeutics has the market capitalization of 1.79B
When is the next Intellia Therapeutics earnings date?▼
Intellia Therapeutics is going to release the next earnings report on November 05, 2026.
What were Intellia Therapeutics earnings last quarter?▼
NTLA earnings for the last quarter are -0.8 USD per share, whereas the estimation was -0.8 USD resulting in a -0.09% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Intellia Therapeutics revenue for the last year?▼
Intellia Therapeutics revenue for the last year amounts to 67.67M USD.
What is Intellia Therapeutics net income for the last year?▼
NTLA net income for the last year is -412.69M USD.
How many employees does Intellia Therapeutics have?▼
As of September 05, 2026, the company has 377 employees.
In which sector is Intellia Therapeutics located?▼
Intellia Therapeutics operates in the Health & Wellness sector.
When did Intellia Therapeutics complete a stock split?▼
Intellia Therapeutics has not had any recent stock splits.
Where is Intellia Therapeutics headquartered?▼
Intellia Therapeutics is headquartered in CAMBRIDGE, United States.